Hyaluronic acid/lactoferrin-coated polydatin/PLGA nanoparticles for active targeting of CD44 receptors in lung cancer

• Published in: Pharmaceutical development and technology 2024-11, Vol.29 (9), p.1016-17
• Main Authors: Nashaat Alnagar, Ahmed, Motawea, Amira, Elamin, Khaled M, Abu Hashim, Irhan Ibrahim
• Format: Article
• Language: English
• Subjects: A549 Cells; Drug Carriers - chemistry; Glucosides - administration & dosage; Glucosides - chemistry; Glucosides - pharmacology; Humans; Hyaluronan Receptors - metabolism; Hyaluronic Acid - chemistry; Lactoferrin - administration & dosage; Lactoferrin - chemistry; Lactoferrin - pharmacology; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Nanoparticles - chemistry; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer - chemistry; Stilbenes - administration & dosage; Stilbenes - chemistry; Stilbenes - pharmacokinetics; Stilbenes - pharmacology
• ISSN: 1083-7450; 1097-9867; 1097-9867
• DOI: 10.1080/10837450.2024.2414937

Traditional chemotherapeutic drugs lack optimal efficacy and invoke severe adverse effects in cancer patients. Polydatin (PD), a phytomedicine, has gradually gained attention due to its antitumor activity. However, its low solubility and poor bioavailability are still cornerstone issues. The present study aimed to fabricate and develop hyaluronic acid/lactoferrin-double coated PD/PLGA nanoparticles a layer-by-layer self-assembly technique for active targeting of CD44 receptors in lung cancer. Different molecular weights (M.wt.) of HA (32 and 110 kDa) were exploited to study the relationship between the HA M.wt. and the NPs targeting efficacy. The optimized formulations were fully characterized. Their cytotoxicity and cellular uptake were investigated against A549 cell line by CCK-8 kit and fluorescence imaging, respectively. Finally, HA110/Lf-coated PD/PLGA NPs (F9) were subjected to a competitive inhibition study to prove internalization through CD44 overexpressed receptors. The results verified the fabrication of F9 with a particle size of 174.87 ± 3.97 nm and a zeta potential of -24.37 ± 1.19 mV as well as spherical NPs architecture. Importantly, it provoked enhanced cytotoxicity (IC = 0.57 ± 0.02 µg/mL) and superior cellular uptake efficacy. To conclude, the current investigation lays the foundation for the prospective therapeutic avenue of F9 for active targeting of CD44 receptors in lung cancer.